Molecular Characterization of ALS/FTD in a novel C9orf72 BAC mouse model.
新型 C9orf72 BAC 小鼠模型中 ALS/FTD 的分子表征。
基本信息
- 批准号:9197026
- 负责人:
- 金额:$ 77.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-01 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute DiseaseAffectAgeAmyotrophic Lateral SclerosisAnimalsAntisense OligonucleotidesAntisense RNAAppearanceBehaviorBehavioralBiological AssayBrainC9ORF72CategoriesCell Culture TechniquesCell MaintenanceCell NucleusCell SurvivalCell physiologyCellsCellular StressCollaborationsCritical PathwaysCytoplasmDefectDevelopmentDipeptidesDiseaseDisease ProgressionElectrophysiology (science)FailureFrontotemporal DementiaFunctional disorderGenesGeneticGenetic TranscriptionIndividualInitiator CodonLaboratoriesLeadLinkLongevityMapsMediatingMethodsMicrosatellite RepeatsMolecularMotorMusMutationNerve DegenerationNuclear ExportNuclear RNAParalysedPathologyPathway AnalysisPathway interactionsPharmacologic SubstancePhasePhysiologicalPlayPopulationPrincipal InvestigatorProductionProteinsRNARNA ProcessingRNA-Binding ProteinsReading FramesReportingResearchRoleSeverity of illnessSiteSpinal CordStagingStressTestingTherapeuticTitrationsToxic effectTranscriptTransgenic MiceTransgenic ModelTranslationsage relatedbasedesigngain of functionin vivoinsightknock-downloss of functionmotor neuron degenerationmouse modelmutantneuron lossnovelpreventprogramsprotein expressionprotein kinase Rtherapeutic developmenttherapeutic targettooltranscriptometranscriptome sequencing
项目摘要
Project Summary
The expansion of a microsatellite GGGGCC repeat in the C9orf72 gene has been linked to both familial and
sporadic forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). While the molecular
basis of this disease (C9-ALS/FTD) remains largely unknown, proposed disease mechanisms include C9orf72
loss of function due to haploinsufficiency, RNA gain of function (GOF) leading to protein sequestration and
repeat-associated non-ATG (RAN) translation resulting in the production of toxic C9-RAN dipeptide repeat
proteins. Based on our prior studies on other microsatellite expansion diseases, this proposal is designed to
test our sequestration failure hypothesis, which integrates RNA and RAN gain of function mechanisms.
According to this hypothesis, bidirectional sense and antisense C9orf72 transcription results in the recruitment
of cellular factors to repeat expansion RNAs to produce sense and antisense RNA foci that sequester these
toxic RNAs in the nucleus. Somatic repeat expansion and/or age-related cellular stress results in titration of
GGGGCC and GGCCCC RNA binding proteins followed by nucleocytoplasmic export of these RNAs and
translation of highly toxic C9-RAN proteins in the cytoplasm that lead to neurodegeneration. We have
generated a BAC transgenic model of C9-ALS/FTD that will allow us to test this hypothesis. This mouse
develops both the molecular (RNA foci, C9-RAN proteins) and pathophysiological (neuronal loss, paralysis,
decreased survival) features of C9-ALS/FTD. In this proposal, we will initially test the hypothesis that RNA
GOF effects precede RAN protein accumulation by performing RNA-FISH, transcriptome analysis and
immunological assays at various developmental periods and in different brain and spinal cord regions on
asymptomatic, pre-symptomatic and symptomatic C9-BAC mice. This information will be used in conjunction
with histopathological and electrophysiological assays test the hypothesis that C9-RAN protein accumulation
triggers neurodegeneration and the acute disease phase. The possibility that stress pathways modulate RAN
translation will also be tested. Finally, we will test whether antisense oligonucleotide (ASO) gapmer-mediated
knockdowns of sense, antisense or both sense and antisense C9orf72 transcripts blocks the development of
RNA and RNA toxicity in our C9-BAC transgenic mice. Overall, the objective of this study is to define
pathogenic mechanisms underlying C9-ALS/FTD disease development and progression and provide an
accessible and well-characterized mouse model for therapeutic development.
项目摘要
C9 orf 72基因中微卫星GGGGCC重复序列的扩增与家族性和
肌萎缩侧索硬化症(ALS)和额颞叶痴呆(FTD)的散发形式。同时分子
这种疾病(C9-ALS/FTD)的基础在很大程度上仍然未知,提出的疾病机制包括C9 orf 72
由于单倍不足导致的功能丧失,RNA功能获得(GOF)导致蛋白质螯合,
重复相关的非ATG(RAN)翻译,导致产生毒性C9-RAN二肽重复
proteins.基于我们先前对其他微卫星扩展疾病的研究,该建议旨在
测试我们的隔离失败假设,它整合了RNA和RAN获得功能机制。
根据这一假设,双向正义和反义C9 orf 72转录导致募集
细胞因子重复扩增RNA,产生有义和反义RNA灶,
细胞核中的有毒RNA。体细胞重复扩增和/或年龄相关的细胞应激导致
GGGGCC和GGCCCC RNA结合蛋白,随后这些RNA的核质输出,
细胞质中高毒性C9-RAN蛋白的翻译导致神经变性。我们有
产生了C9-ALS/FTD的BAC转基因模型,这将使我们能够检验这一假设。这个鼠标
发展分子(RNA灶,C9-RAN蛋白)和病理生理(神经元丢失,麻痹,
C9-ALS/FTD的存活率降低)特征。在这个提议中,我们将首先检验RNA
通过进行RNA-FISH、转录组分析和
在不同发育时期和不同脑和脊髓区域的免疫测定,
无症状、症状前和有症状的C9-BAC小鼠。这些信息将与
用组织病理学和电生理学分析测试C9-RAN蛋白积累
引发神经退化和急性期应激途径调节RAN的可能性
翻译也将受到考验。最后,我们将测试反义寡核苷酸(阿索)缺口体介导的
有义、反义或有义和反义C9 orf 72转录物的敲低阻断了
我们的C9-BAC转基因小鼠中的RNA和RNA毒性。总的来说,本研究的目的是确定
C9-ALS/FTD疾病发展和进展的致病机制,并提供了一个
用于治疗开发的可获得且充分表征的小鼠模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Laura P.W Ranum其他文献
Laura P.W Ranum的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Laura P.W Ranum', 18)}}的其他基金
Molecular Characterization of ALS/FTD in a novel C9orf72 BAC mouse model.
新型 C9orf72 BAC 小鼠模型中 ALS/FTD 的分子表征。
- 批准号:
9751987 - 财政年份:2016
- 资助金额:
$ 77.36万 - 项目类别:
Molecular Characterization of ALS/FTD in a novel C9orf72 BAC mouse model.
新型 C9orf72 BAC 小鼠模型中 ALS/FTD 的分子表征。
- 批准号:
9335570 - 财政年份:2016
- 资助金额:
$ 77.36万 - 项目类别:
Molecular effects of metformin, PKR and TBI on C9orf72 ALS/FTD
二甲双胍、PKR 和 TBI 对 C9orf72 ALS/FTD 的分子效应
- 批准号:
10586260 - 财政年份:2016
- 资助金额:
$ 77.36万 - 项目类别:
7th International Conference on Unstable Microsatellites in Human Disease
第七届人类疾病不稳定微卫星国际会议
- 批准号:
8323030 - 财政年份:2012
- 资助金额:
$ 77.36万 - 项目类别:
2011 CAG Triplet Repeat Disorders GRC/GRS
2011 CAG 三联体重复疾病 GRC/GRS
- 批准号:
8125467 - 财政年份:2011
- 资助金额:
$ 77.36万 - 项目类别:
Myotonic Dystrophy: Molecular Pathophysiology and CNS Effects
强直性肌营养不良:分子病理生理学和中枢神经系统影响
- 批准号:
8609099 - 财政年份:2008
- 资助金额:
$ 77.36万 - 项目类别:
REPEAT-ASSOCIATED NON-ATG TRANSLATION IN DM1 AND DM2
DM1 和 DM2 中重复相关的非 ATG 翻译
- 批准号:
8739677 - 财政年份:2008
- 资助金额:
$ 77.36万 - 项目类别:
Myotonic Dystrophy: Molecular Pathophysiology and CNS Effects
强直性肌营养不良:分子病理生理学和中枢神经系统影响
- 批准号:
8257590 - 财政年份:2008
- 资助金额:
$ 77.36万 - 项目类别:
Myotonic Dystrophy: Molecular Pathophysiology and CNS Effects
强直性肌营养不良:分子病理生理学和中枢神经系统影响
- 批准号:
8303500 - 财政年份:2008
- 资助金额:
$ 77.36万 - 项目类别:
相似海外基金
Improving Acute Disease Management for Patients with Alzheimer's Disease and Related Dementias
改善阿尔茨海默病和相关痴呆症患者的急性疾病管理
- 批准号:
10712647 - 财政年份:2001
- 资助金额:
$ 77.36万 - 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
- 批准号:
6247642 - 财政年份:1997
- 资助金额:
$ 77.36万 - 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
- 批准号:
3718999 - 财政年份:
- 资助金额:
$ 77.36万 - 项目类别:
Neurophysiological alterations in multiple sclerosis patients during acute disease acivity
多发性硬化症患者急性疾病活动期间的神经生理学变化
- 批准号:
465668867 - 财政年份:
- 资助金额:
$ 77.36万 - 项目类别:
Research Grants
SIVMAC 1NEF ALLELE: LYMPHOCYTE ACTIVATION & ACUTE DISEASE IN MACAQUE MONKEYS
SIVMAC 1NEF 等位基因:淋巴细胞激活
- 批准号:
3719026 - 财政年份:
- 资助金额:
$ 77.36万 - 项目类别: